LOS ANGELES, CA / ACCESSWIRE / November 30, 2016 / AzurRx BioPharma, Inc. (NASDAQ: "AZRX"), a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions, announced today that it will be presenting at the 9th annual LD Micro Main Event on Tuesday, December 6th at 12:30PM PST / 3:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Thijs Spoor, (President and CEO of AzurRx BioPharma, Inc.) will be presenting, as well as meeting with investors.
The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.
View AzurRx BioPharma's profile here: http://www.ldmicro.com/profile/AZRX
News Compliments of Accesswire
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the company can be found at www.azurrx.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
Name: Thijs Spoor
Address: AzurRx BioPharma, Inc., 760 Parkside Avenue, Suite 217, Brooklyn, NY 11226